COVID-19 (Coronavirus disease) is an infectious disease caused by the most recently discovered coronavirus, SARS-CoV-2 (2019-nCoV).
The SARS-CoV-2 Rapid Diagnostic Test provides qualitative detection of IgG and/or IgM from human serum, whole blood, or plasma in approximately 10-15 minutes.
Rapid tests are based on the principle of lateral flow immunoassay chromatography and are available in cassette form. The test is based on the separation of the components of a mixture through a medium by capillary force and the rapid and specific binding of an antibody to its antigen.
IgM and IgG are immunoglobulins produced by the immune system to provide protection against SARS-CoV-2. Therefore, anti-SARS-CoV-2 IgM and IgG can be detected in samples from affected patients.
We offer several types of kits to detect IgG or IgM or both at the same time. We also offer kits containing only the cassettes and other complete kits for sampling and analysis. All these kits are for in vitro diagnostic use and can only be used by healthcare professionals.
What are the advantages of rapid tests:
- Rapid detection in 10-15 minutes.
- High detection efficiency: simultaneous monitoring of IgM and IgG.
- Detection without test equipment.
- Easy to operate and compatible with serum / whole blood/plasma.
- Storage at room temperature.
- What is the principle of rapid tests for SARS-CoV-2?
The test detects the presence of patient-generated antibodies against SARS-CoV-2, the virus that causes COVID-19 disease. The test can detect two types of antibody isotypes: IgG and IgM.
There are several types of tests, but the most common is to fix anti-human IgG and IgM antibodies to the surface of the cassette and couple a virus antigen with colloidal gold particles. If the patient sample contains anti-SARS-CoV-2 antibodies, then these antibodies will bind to the antigen present on the conjugation pad of the cassette and the complex formed will migrate to the membrane-bound anti-human IgG and/or IgM. Then a colored band will appear (see possible results below).
The level of IgM antibodies begins to rise after 1 week after the initial infection, while IgG appears later than IgM (usually 14 days after infection) and can last for 6 months or even several years, which means that IgG serves as an indicator of the previous infection.
Patients suspected of being infected with SARS-CoV-2 can be quickly identified by simultaneous monitoring of IgM and IgG. During the period of the 2003-SARS and 2016-Zika outbreaks, the detection of IgM / IgG antibodies was used as one of the recommended diagnostic methods.
There are different cassettes for rapid tests. In general, for the qualitative detection of IgG and IgM at the same time, there are 3 different lines: one for IgG, one for IgM, and one for the control.